These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15194545

  • 1. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
    Hohaus S, Di Febo A, Storti S, Teofili L, Voso MT, Leone G.
    Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
    [Abstract] [Full Text] [Related]

  • 2. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 3. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 4. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease.
    Aversa SM, Salvagno L, Sorarù M, Mazzarotto R, Boso C, Gaion F, Chiarion-Sileni V, De Franchis G, Favaretto AG, Crivellari G, Banna GL, Sotti G, Monfardini S.
    Acta Haematol; 2004 May 01; 112(3):141-7. PubMed ID: 15345896
    [Abstract] [Full Text] [Related]

  • 5. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST, Miller TP.
    Curr Hematol Rep; 2004 Jan 01; 3(1):17-26. PubMed ID: 14695845
    [Abstract] [Full Text] [Related]

  • 6. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 7. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Oliveira JS.
    Ann Hematol; 2009 Jul 15; 88(7):633-7. PubMed ID: 18998131
    [Abstract] [Full Text] [Related]

  • 8. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):19-30. PubMed ID: 17097834
    [Abstract] [Full Text] [Related]

  • 9. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
    Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
    J Clin Oncol; 2009 Nov 10; 27(32):5390-6. PubMed ID: 19738111
    [Abstract] [Full Text] [Related]

  • 10. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, Pruneri G, Mazzetta C, Ghielmini M, Cavalli F.
    Br J Haematol; 2004 Jun 10; 125(5):584-9. PubMed ID: 15147373
    [Abstract] [Full Text] [Related]

  • 11. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
    Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC, British National Lymphoma Investigation, Central Lymphoma Group.
    Br J Cancer; 2001 May 18; 84(10):1293-300. PubMed ID: 11355937
    [Abstract] [Full Text] [Related]

  • 12. Pediatric Hodgkin's disease.
    Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ, Paris KJ, Silverman CL, Yashar CM.
    J Ky Med Assoc; 2004 Mar 18; 102(3):104-6. PubMed ID: 15067795
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 14. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M.
    J Clin Oncol; 2009 Sep 20; 27(27):4548-54. PubMed ID: 19704068
    [Abstract] [Full Text] [Related]

  • 15. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K, Utsumi M, Shimoyama M.
    Gan To Kagaku Ryoho; 1998 Dec 20; 25(14):2202-9. PubMed ID: 9881076
    [Abstract] [Full Text] [Related]

  • 16. [The chemotherapeutic treatment of advanced Hodgkin's disease].
    Epelbaum R, Haim N, Ben-Shahar M, Valtuch I, Faraggi D, Sharabi-Nov A, Ben-Arie Y, Cohen Y.
    Harefuah; 2001 Apr 20; 140(4):311-5, 367. PubMed ID: 11303395
    [Abstract] [Full Text] [Related]

  • 17. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.
    J Clin Oncol; 1995 May 20; 13(5):1080-8. PubMed ID: 7537796
    [Abstract] [Full Text] [Related]

  • 18. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.
    Ai Zheng; 2006 Aug 20; 25(8):1013-8. PubMed ID: 16965685
    [Abstract] [Full Text] [Related]

  • 19. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M.
    J Clin Oncol; 2006 Jul 01; 24(19):3128-35. PubMed ID: 16754934
    [Abstract] [Full Text] [Related]

  • 20. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P.
    Eur J Cancer; 2005 May 01; 41(7):998-1006. PubMed ID: 15862748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.